Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal(GI) Ulcer

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01215058
First received: September 28, 2010
Last updated: October 21, 2010
Last verified: October 2010
  Purpose

The purpose of this study is to assess gastroprotective agent compliance in patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer with NSAID.


Condition
Gastrointestinal Hemorrhage
Ulcer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Gastroprotective Agent Compliance in Patients at Risk Suffering From a Gastrointestinal Bleeding Ulcer or a Symptomatic Ulcer With Non-steroidal Anti-inflammatory Drug (NSAID) in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Gastroprotective agent compliance [ Time Frame: At the end of 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Clinical characteristics of those ulcers with NSAID [ Time Frame: At the end of 1 month ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: October 2010
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Hospital sample

Criteria

Inclusion Criteria:

  • Patients at risk suffering from a gastrointestinal bleeding ulcer or a symptomatic ulcer confirmed by endoscopy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01215058

Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Jean-Francois Bretagne Service gastro-enterologie et hepatologieCHRU Pontchaillou35033 RENNES cedex France
Study Chair: Gerard Thiefin Service Hepato-Gastroenterologie CHU Reims51092 REIMS cedex France
Principal Investigator: Genevieve BONNELYE KantarHealth - France138, avenue Marx Dormoy92120 Montrouge cedex
  More Information

No publications provided

Responsible Party: Marketing Company Medical Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT01215058     History of Changes
Other Study ID Numbers: NIS-PFR-DUM-2010/2
Study First Received: September 28, 2010
Last Updated: October 21, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Compliance, France
Gastrointestinal bleeding ulcer or symptomatic ulcer with NSAID

Additional relevant MeSH terms:
Gastrointestinal Hemorrhage
Hemorrhage
Ulcer
Digestive System Diseases
Gastrointestinal Diseases
Pathologic Processes
Anti-Inflammatory Agents, Non-Steroidal
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014